Clinical milestone achieved.

No definition available.

Name:	aclx_ClinicalMilestoneAchieved
Namespace Prefix:	aclx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaboration And License Agreement Non Refundable Upfront Payment Received

+ References

No definition available.

+ Details

Name:	aclx_CollaborationAndLicenseAgreementNonRefundableUpfrontPaymentReceived
Namespace Prefix:	aclx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Discount on shares sold/issued to related parties.

+ References

No definition available.

+ Details

Name:	aclx_DiscountOnSharesSoldIssuedToRelatedParties
Namespace Prefix:	aclx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Discount on shares sold/issued to related party.

+ References

No definition available.

+ Details

Name:	aclx_DiscountOnSharesSoldIssuedToRelatedParty
Namespace Prefix:	aclx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Percentage of out-of-pocket development costs for co-promote products.

+ References

No definition available.

+ Details

Name:	aclx_PercentageOfOutOfPocketDevelopmentCostsForCoPromoteProducts
Namespace Prefix:	aclx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential payments of clinical milestone.

+ References

No definition available.

+ Details

Name:	aclx_PotentialPaymentsOfClinicalMilestone
Namespace Prefix:	aclx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Potential payments of commercial milestone.

+ References

No definition available.

+ Details

Name:	aclx_PotentialPaymentsOfCommercialMilestone
Namespace Prefix:	aclx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Potential payments of regulatory milestone.

+ References

No definition available.

+ Details

Name:	aclx_PotentialPaymentsOfRegulatoryMilestone
Namespace Prefix:	aclx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Premium on shares sold/issued to related party.

+ References

No definition available.

+ Details

Name:	aclx_PremiumOnSharesSoldIssuedToRelatedParty
Namespace Prefix:	aclx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A

+ Details

Name:	us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

+ Details

Name:	us-gaap_SharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name:	us-gaap_SharesIssuedPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	srt_ProductOrServiceAxis=aclx_AnitoCelMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=aclx_AnitoCelNextGenNonautologousMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=aclx_KiteCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=aclx_KiteCollaborationAgreementAndAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=aclx_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=aclx_AmendedKiteCollaborationAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=aclx_GileadCommonStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=aclx_GileadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=aclx_SecondGileadCommonStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreement - Additional Information (Details) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2023	Jan. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 28, 2023	Jan. 26, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance of private placement				$ 299,706,000	$ 9,958,000
Contract with customer, performance obligation satisfied in previous period			$ 0
Unrecognized revenue			50,200,000
Anito-cel in rrMM
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Clinical milestone achieved			68,300,000
Anito-cel Next Gen Non-autologous \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential payments of clinical milestone			530,000,000
Potential payments of regulatory milestone			935,000,000
Potential payments of commercial milestone			$ 507,500,000
Kite Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment received	$ 85,000,000	$ 225,000,000
Reduction of deemed discount on shares sold							$ 15,300,000
Increase in deemed premium on shares sold						$ 15,600,000
Kite Collaboration Agreement and Amendment \| United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of out-of-pocket development costs for co-promote products			40.00%
Kite Collaboration Agreement and Amendment \| Kite Pharma, Inc. \| Outside United States
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of out-of-pocket development costs for co-promote products			60.00%
Amended Kite Collaboration Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment received	$ 85,000,000
Gilead Common Stock Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares purchased			3,478,261
Shares issued, price per share			$ 28.75
Reduction of deemed discount on shares sold		15,300,000
Gilead Common Stock Purchase Agreement \| Gilead
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance of private placement		$ 100,000,000
Second Gilead Common Stock Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares purchased	3,242,542		3,242,542	3,242,542
Shares issued, price per share	$ 61.68		$ 61.68	$ 61.68
Increase in deemed premium on shares sold	$ 15,600,000			$ 15,600,000
Second Gilead Common Stock Purchase Agreement \| Gilead
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance of private placement	$ 200,000,000